Vol 1, No 2 (December 01, 2012): Chinese Clinical Oncology

The importance of surgical oncology in China: a view from across the ocean

Perspectives in drug development for cancer therapy in Asia

Clinical practice guidelines on cancer-related anemia (2012-2013 Edition)

Risk of venous thromboembolism with the erythropoiesisstimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials

The latest meta-analysis on the use of erythritopoiesis-stimulating agents in chemotherapy induced anaemia brings new light on the safety

Intravenous iron for treating cancer-induced anemia: meeting an unmet need?

Is it time for erythropoietin use in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients?

Is it already time for combination treatment in lower risk MDS?

Breakthrough in tracking tumor erythropoietin receptor expression

High-dose recombinant human erythropoietin for “low-risk” myelodysplastic patients: is more better?

Erythropoietin and cancer - a poorly understood liaison!

Sandra M. Swain: follow your passion at work

Charles M. Balch: specializing surgeons is going to be a trend

Claus-Henning Koehne: the awareness of K-Ras is a great progress in molecular targeted therapy

Rik J Scheper: European Regulations on cell therapy, going too far?